Showing 11-20 of 3009 results for "".
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- New Insights into ARIA-E Risk from Donanemab Studieshttps://practicalneurology.com/news/new-insights-into-aria-e-risk-from-donanemab-studies/2470464/In an effort to understand more about amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapy, researchers analyzed pooled data from 3 studies involving donanemab (Eli Lilly and Company, Indianapolis, IN) therapy for individuals with early Alzheimer disease (AD):
- CTAD 2025 Honors Takeshi Iwatsubo, MD, PhD with Lifetime Achievement Awardhttps://practicalneurology.com/news/ctad-2025-honors-takeshi-iwatsubo-md-phd-with-lifetime-achievement-award/2484692/Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. The award celebrates Dr. Iwatsubo’s decades of foundational work in Alzheime
- Catherine Chu, MD, to Lead Pediatric Neurology at Kennedy Krieger and Johns Hopkinshttps://practicalneurology.com/news/catherine-chu-md-to-lead-pediatric-neurology-at-kennedy-krieger-and-johns-hopkins/2475483/Catherine Chu, MD, MA, MMSc, has been named Vice President of Child Neurology of the Kennedy Krieger Institute and will also serve as Director of the Division of Pediatric Neurology and the John M. Freeman Pediatric Epilepsy Center at Johns Hopkins Children’s Center. According to a statement rele
- In Memoriam: Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANAhttps://practicalneurology.com/news/in-memoriam-martin-a-samuels-md-dsc-hon-faan-macp-frcp-fana/2470226/Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANA, the first named Miriam Sydney Joseph Distinguished Professor of Neurology at Harvard Medical School, passed away on June 6, 2023, at age 77.
- Oral Edaravone Well-Tolerated as ALS Therapyhttps://practicalneurology.com/news/oral-edaravone-well-tolerated-as-als-therapy/2470134/Oral e
- Jeffrey Cohen, MD, Delivers Kenneth P. Johnson Memorial Lecture at ACTRIMS 2026https://practicalneurology.com/news/jeffrey-cohen-md-delivers-kenneth-p-johnson-memorial-lecture-at-actrims-2026/2485637/The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) has honored Jeffrey Cohen, MD, with the 2026 Kenneth P. Johnson Memorial Lecture, recognizing his longstanding contributions to multiple sclerosis (MS) research, clinical care, and leadership. The annual memorial le
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- Enhanced Kisunla Dosing Regimen Reduced ARIA-E Risk While Maintaining Amyloid Reduction in Early Alzheimer Diseasehttps://practicalneurology.com/news/enhanced-kisunla-dosing-regimen-reduces-aria-e-risk-while-maintaining-amyloid-reduction-in-early-alzheimer-disease/2470624/Results from the multicenter, randomized, double-blind, phase 3b TRAILBLAZER-ALZ 6 (NCT05738486) clinical trial revealed that an enhanced dosing regimen for Kisunla (donanemab; Eli Lilly and Company, Indianapolis, IN) significantly reduces the frequency and severity of amyloid-related imaging abn